Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and
Several prospective monocentric cohorts of between 250 and 1000 patients have been set up in order to characterize more precisely the evolution of the disease. Nevertheless, due to an initial recruitment carried out in the years 2000-2010, they do not constitute a faithful representation of the patients followed in cli
| Condition(s) | Multiple Sclerosis |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Several prospective monocentric cohorts of between 250 and 1000 patients have been set up in order to characterize more precisely the evolution of the disease. Nevertheless, due to an initial recruitment carried out in the years 2000-2010, they do not constitute a faithful representation of the patients followed in clinical routine, in particular in terms of distribution of treatments. Indeed, the introduction, about 10 years ago, of high efficacy treatments (HET) has changed the management of the disease and a significant proportion of patients not controlled by medium efficacy treatments (MET) of the disease are now stable on HET. Nevertheless, if their short-term efficacy has been clearly demonstrated, it remains important to be able to confirm the superiority of HET over MET with the h |
| Who can participate | Inclusion Criteria: * Patients over 18 and under 60 years of age * Patients with Relapsing-remitting MS without relapse for at least 6 months * EDSS\<6 at time of inclusion Exclusion Criteria: * Secondary progressive MS or Primary progressive MS at time of inclusion * Evidence of disease progression (clinical or radiological) * Change in treatment within 6 months prior to inclusion * Subject with a contraindication to MRI (claustrophobia, pacemaker, etc.) * Inability to follow the follow-up planned by the study * Pregnant or breastfeeding women * Patient not affiliated to the social security system or not benefiting from such a system * Adult protected by law or patient under guardianship or curatorship * Failure to obtain written informed consent after a reflection period |
| Ages | 18 Years to 59 Years |
| Sex | All |
| Lead sponsor | University Hospital, Montpellier |
| Locations | Montpellier, France |
| Start date | 2023-09-11 |
| NCT ID | NCT05962177 |
| Official listing | https://clinicaltrials.gov/study/NCT05962177 |